{"id":"mircette","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL1533","moleculeType":"Small molecule","molecularWeight":"310.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mircette contains desogestrel (a progestin) and ethinyl estradiol (an estrogen) in a biphasic formulation, with a 7-day hormone-free interval followed by 2 days of estrogen-only pills. The progestin inhibits the luteinizing hormone surge necessary for ovulation, while the estrogen suppresses follicle-stimulating hormone to prevent follicle development. The estrogen-only phase during the final days may reduce breakthrough bleeding.","oneSentence":"Mircette is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:33.437Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"}]},"trialDetails":[{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT01005056","phase":"","title":"Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Contraception","enrollment":3838},{"nctId":"NCT00544882","phase":"PHASE3","title":"A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-10-31","conditions":"Healthy","enrollment":61},{"nctId":"NCT01252186","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2010-11","conditions":"Hemostasis, Oral Contraceptive","enrollment":265},{"nctId":"NCT01616225","phase":"PHASE2, PHASE3","title":"Growth Hormone in Poor Responders to IVF Trial","status":"TERMINATED","sponsor":"Pacific Centre for Reproductive Medicine","startDate":"2012-06","conditions":"Infertility","enrollment":60},{"nctId":"NCT00826839","phase":"PHASE4","title":"Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Infertility","enrollment":""},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01298128","phase":"NA","title":"NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment","status":"TERMINATED","sponsor":"University of Toronto","startDate":"2006-02","conditions":"Infertility, In-vitro Fertilization","enrollment":70},{"nctId":"NCT00185419","phase":"PHASE3","title":"A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Contraception","enrollment":842}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["desogestrel/ethinyl estradiol"],"phase":"phase_3","status":"active","brandName":"Mircette®","genericName":"Mircette®","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mircette is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen hormones. Used for Contraception (prevention of pregnancy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}